wegovy will be offered on the NHS in England to about 1. 2 million people who are overweight and at risk of further heart attacks and strokes, marking a clear inflection in eligibility for semaglutide-based care.
What Is the Current State of Play?
National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending semaglutide for people with a body mass index of 27 or above who have already had a heart attack, stroke or a serious circulation problem in their legs. NHS England said around 1. 2 million people could benefit, and officials expect the newly eligible group to be able to access the drug within months. Semaglutide is already available on the health service for some people living with obesity and is also offered under the brand name Ozempic to treat type 2 diabetes.
- Eligibility: BMI 27+ with prior heart attack, stroke or serious peripheral circulation problem (NICE).
- Scale: Approximately 1. 2 million people could become eligible (NHS England).
- Delivery: Weekly injections added to existing heart medicines such as statins, alongside diet and increased physical activity (NICE).
- Regulatory status: NICE guidance is currently draft; NHS England anticipates access within months.
What Happens When Wegovy Is Offered to People at Risk?
The clinical evidence underpinning the decision emphasises cardiovascular benefit beyond weight loss. Clinical trials demonstrated that semaglutide reduces the risk of heart attack, stroke or cardiovascular death, and NICE highlighted that this benefit appeared before significant weight loss, indicating direct effects on the heart and blood vessels. A large study led by University College London and published in the Lancet found semaglutide cuts the risk of heart attack or stroke regardless of how many kilograms people lose. Earlier analyses identified reductions in major cardiac events in the region of 20%.
Helen Knight, director of medicines evaluation at NICE, described the UCL findings as compelling and emphasised that people taking semaglutide alongside existing heart medicines were significantly less likely to have another heart attack or stroke. Helen Williams, NHS England’s clinical director for cardiovascular disease prevention, said offering this treatment to more than a million people at high risk could be life-changing and provide an extra layer of protection.
What Should Patients and Clinicians Do Next?
Clinicians will need to integrate the injections with current secondary prevention strategies — continuing statins and other heart medicines, and reinforcing reduced-calorie diets and increased physical activity. The guidance is draft, so local pathways and prescribing arrangements will follow NICE’s final recommendation and NHS England implementation planning.
There is uncertainty in how quickly services will scale, how clinicians will prioritise patients within the newly eligible group, and how ongoing monitoring will be organised. Decision-makers should prepare to manage demand, align multidisciplinary care, and communicate clearly with patients about the role of semaglutide as an additional layer of protection rather than a replacement for established therapies. For patients and clinicians alike, the immediate imperative is to anticipate new referral pathways and evaluate individual risk profiles in line with NICE criteria, keeping a clear eye on outcomes as access widens to wegovy
